Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of High-Dose Radiation Therapy Combined with Goserelin for High-Risk Prostate Cancer Patients Using AI-Based Treatment Planning

Registered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with prostate cancer who will receive a combination of two treatments: radiotherapy and hormone therapy using goserelin. The hormone therapy involves using a medication that is given as an implant under the skin. The study aims to personalize treatment using advanced imaging techniques including PET/CT scans and artificial intelligence to determine the most appropriate treatment plan for each patient.

The treatment involves high-dose radiation therapy delivered in 6 sessions, specifically targeting the prostate. This is combined with androgen deprivation therapy (hormone treatment that reduces male hormone levels) using goserelin implants. The radiation treatment is guided by special scans that use a substance called PSMA (prostate-specific membrane antigen) to create detailed images of the prostate.

The study will use artificial intelligence to analyze various medical images and information to help determine the best treatment approach. This includes looking at special prostate scans called magnetic resonance imaging (MRI) along with other tests. The treatment period will last several months, during which patients will receive both radiation therapy and hormone treatment, and their progress will be monitored for several years afterward.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial Treatment Phase

    You will receive hormone therapy (goserelin) through implantation to reduce testosterone levels

    This treatment will be combined with targeted radiation therapy to the prostate

    The radiation therapy will be delivered in 6 treatment sessions

  2. Step 2

    Treatment Monitoring

    Your PSA levels will be regularly monitored

    You will undergo periodic imaging scans (PSMA-PET/CT or MRI) to check treatment effectiveness

    Regular assessment of side effects related to urinary and digestive systems will be conducted

  3. Step 3

    Quality of Life Assessment

    You will complete questionnaires about your quality of life

    These forms will assess urinary function, digestive health, and other aspects of daily living

    Your testosterone levels will be monitored during recovery

  4. Step 4

    Long-term Follow-up

    Your health status will be monitored for up to 5 years after treatment completion

    Regular check-ups will include PSA testing and imaging scans as needed

    Any changes in your health condition will be documented and addressed

Who can join the trial?

10 criteria

  • Patient must have confirmed prostate cancer through tissue examination (biopsy), with testing done preferably within the last 12 months
  • Must provide the prostate biopsy sample with the highest ISUP grade (a system that grades how aggressive the cancer appears under microscope)
  • Must have high-risk or very high-risk prostate cancer according to current medical guidelines
  • Cancer must be confined to the prostate as shown on special imaging tests (PSMA-PET and MRI scans)
  • Must provide signed informed consent to participate in the study
  • Must be over 18 years old
  • Must have previously undergone specific imaging tests: PSMA-PET/CT, detailed MRI, or PSMA-PET/MR
  • Must be classified as low or intermediate risk by artificial intelligence assessment
  • Must have good physical function status (ECOG score of 0 or 1, meaning able to carry out all or most daily activities)
  • Must have acceptable urinary symptoms (IPSS Score of 15 or less, which measures urinary problems)

Who cannot join the trial?

15 criteria

  • Prior radiation therapy to the pelvic area
  • Active inflammatory bowel disease (chronic conditions affecting the digestive tract such as Crohn's disease or ulcerative colitis)
  • History of hip replacement surgery
  • Presence of metastases (cancer that has spread to other parts of the body)
  • Inability to lie still for the required imaging and treatment procedures
  • Severe urinary symptoms requiring catheterization
  • Previous treatment with chemotherapy for prostate cancer
  • Presence of other active cancers (except for non-melanoma skin cancer)
  • Severe heart or lung disease that could interfere with treatment
  • Known allergies to contrast agents used in imaging
  • Mental conditions that could affect ability to provide informed consent
  • Participation in other clinical trials within the past 30 days
  • Female patients (study is specifically for male patients)
  • Age below 18 years
  • Contraindications to hormone therapy (treatment that affects male hormones)
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Androgen Deprivation Therapy (ADT) This is a hormonal therapy that reduces testosterone levels in the body. It's commonly used to treat prostate cancer by slowing down the growth of cancer cells that depend on testosterone to grow. Radiotherapy This is a targeted treatment that uses high-energy radiation beams to destroy cancer cells in the prostate. In this trial, it's being delivered in an ultra-hypofractionated format, which means higher doses are given over fewer treatment sessions (6 fractions), making the overall treatment time shorter for patients. The trial also uses PSMA PET/CT imaging for guidance, but this is a diagnostic tool rather than a treatment.

What is already known about the treatment

  • Androgen Deprivation Therapy (ADT)

    This is a hormonal treatment given as periodic injections or oral medications that reduces testosterone levels in the body for the treatment of prostate cancer. This therapy works by blocking the production or the effect of the male hormones that can stimulate prostate cancer growth, and it is particularly effective when combined with radiotherapy. The treatment belongs to the pharmacological class of antiandrogens and is commonly used in cases of high-risk prostate cancer, working by suppressing the hormonal signaling that promotes tumor growth.

  • PSMA PET/CT

    This is a diagnostic imaging technique that uses a specific radioactive tracer that attaches to prostate cancer cells, allowing them to be visualized with a combined positron emission tomography and computed tomography scan. This advanced technique is administered intravenously and provides detailed images of the location and extent of the prostate cancer, helping doctors plan more precise and personalized treatments. It is classified as a diagnostic imaging agent and is especially useful for staging and monitoring prostate cancer.

Investigated diseases

Prostate Cancer - A disease that develops in the prostate gland, which is part of the male reproductive system. The condition typically begins when normal prostate cells start to grow uncontrollably, forming a tumor. This cancer usually grows slowly in its early stages, and most cases develop in men over the age of 50. The disease can remain localized within the prostate or spread to nearby tissues. Prostate cancer often develops without noticeable early symptoms, and its progression can vary significantly between individuals.
Trial detailsLast updated 30 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-510707-11-00Protocol codeHypoProEstimated enrolment30 patientsSponsorLinac-Pet Scan Opco Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.